Mini-review

Recent updates on the role of extracellular vesicles in the pathogenesis of allergic asthma

Ashokkumar Srinivasan, Isaac Kirubakaran Sundar

Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Kansas Medical Center, Lawrence, KS 66160, USA.

Correspondence to: Dr. Isaac K. Sundar, PhD, Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Kansas Medical Center, Lawrence, KS 66160, USA. E-mail: isundar@kumc.edu

How to cite this article: Srinivasan A, Sundar IK. Recent updates on the role of extracellular vesicles in the pathogenesis of allergic asthma. Extracell Vesicles Circ Nucleic Acids 2021;2:127-47. http:/dx.doi.org/10.20517/evcna.2021.03

Received: 27 Jan 2021  First Decision: 26 Feb 2021  Revised: 12 Mar 2021  Accepted: 17 Mar 2021  Published: 12 May 2021

Academic Editor: Chulhee Choi  Copy Editor: Yue-Yue Zhang  Production Editor: Yue-Yue Zhang

Abstract

Asthma is a chronic inflammatory disease of the airway diagnosed with different endotypes and phenotypes, characterized by airway obstruction in response to allergens, bacterial/viral infections, or pollutants. Several cell types such as the airway epithelial cells, mesenchymal stem cells and different immune cells including dendritic cells (DCs), T and B cells and mast cells play an essential role during the pathobiology of asthma. Extracellular vesicles (EVs) are membranous nanovesicles produced by every cell type that facilitates intercellular communications. EVs contain heterogeneous cargos that primarily depend on the composition or cell type of origin and they can alter the physiological state of the target cells. EVs encompass a wide variety of proteins including Tetraspanins, MHC classes I and II, co-stimulatory molecules, nucleic acids such as RNA, miRNA, piRNA, circRNA, and lipids like ceramides and sphingolipids. Recent literature indicates that EVs play a pivotal role in the pathophysiology of allergic asthma and may potentially be used as a novel biomarker to determine endotypes and phenotypes in severe asthmatics. Based on the prior reports, we speculate that regulation of EVs biogenesis and release might be under the control of circadian rhythms. Thus, circadian rhythms may influence the composition of the EVs, which alter the microenvironment that results in the induction of an immune-inflammatory response to various environmental insults or allergens such as air pollutants, ozone, diesel exhaust particles, pollens, outdoor molds, environmental tobacco smoke, etc. In this mini-review, we summarize the recent updates on the novel role of EVs in the pathogenesis of asthma, and highlight the link between circadian rhythms and EVs that may be important to identify molecular mechanisms to target during the pathogenesis of chronic inflammatory lung disease such as asthma.

Keywords: Asthma, extracellular vesicles, biomarkers, miRNAs, chronic lung disease

© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

www.evcna.com
INTRODUCTION
Asthma is a chronic airway disorder and generally characterized by various symptoms like bronchial hyperreactivity, airway obstruction and inflammation-induced airway remodeling. It was previously described as simple allergic airway inflammation treated with antihistamine and prophylactic agents. Nevertheless, as our understanding of asthma grew deep and wide, it could no longer be considered as a diagnosis term like Parkinson’s or Alzheimer’s. It is an umbrella term that collectively describes the clinical symptoms such as wheezing, breathlessness, chest tightness and cough followed by etiology of asthma. Asthma may be manifested as different endotypes and phenotypes (young atopic, obese middle-aged and elderly asthma). Asthmatics develop clinical symptoms as a result of exposure to different environmental agents that ultimately affect the pathophysiology of the disease\[^1,2\].

Allergens, air pollutants/particulates, ozone, diesel exhaust particles, pollens, microbial infections both bacterial and viral, outdoor molds, environmental tobacco smoke, obesity, exercise, cold air, humidity, genetic predisposition are among the known factors that lead to asthmatic complication either as a result of acute or chronic exposure. Until recently, all asthmatic patients were treated with the same medication. However, this resulted in varying responses to therapies due to the diverse nature of the disease. Therefore, identifying asthma based on the endotype is clinically important to personalize medication for the patients. Asthma is defined as a T2 and non-T2 endotype that includes a range of phenotypes that have similar symptoms, but varying pathophysiology\[^3\]. T2 high endotype has three phenotypes [atopic, late-onset, Aspirin exacerbated respiratory disease] and non-T2 endotype has four phenotypes including non-atopic, smokers, obesity-related and elderly asthma. Both innate and adaptive immunity directly regulate asthma phenotypes along with the involvement of immune cells that play a crucial role in the pathogenesis of asthma. Epithelial cells and dendritic cells (DCs) play a major role in determining the type of T helper cells differentiation and activation via cytokine secretion and antigen presentation\[^4,5\]. Apart from cytokines, the participation of exosomes in determining the type of immune response elicited against an allergen or environmental insult, is also increasingly getting attention in recent years\[^6,7\]. In this review, we discuss the concept of extracellular vesicles (EVs) in determining the endotypes and phenotypes of asthma following exposure to different environmental insults. Understanding the novel role of EVs will help in finding new therapeutic targets for severe asthma that has a very poor clinical outcome.

Extracellular vesicles
EVs are heterogenous membranous vesicles that cannot replicate (lack of functional nucleus), which includes exosomes, ectosomes and apoptotic bodies. Based on the size, EVs can be classified as exosomes or small EVs (50-200 nm) or Ectosomes (< 200 nm) or apoptotic bodies (200-5000 nm). Exosomes are nano-sized vesicles made up of lipid bilayer membranes enclosing various mixtures of biological molecules, like DNA, RNA, proteins, and lipids\[^8,9\]. Exosomes cannot be defined based on their size, as the size range overlaps with the size of microvesicles. Therefore, exosomes are defined based on the mechanism of biogenesis from the host cell. Exosomes are produced by the inward invagination of endosome membrane forming multivesicular bodies (MVB) and ultimately released out of the cell by fusion of MVB with the plasma membrane (exosomes are smaller than MVB themselves)\[^8,9\]. In contrast, ectosomes (microvesicles or microparticles ~100-1000 nm in diameter) are produced by outward budding of the plasma membrane. The last class of EVs are called apoptotic bodies, which are considered as cellular debris and disregarded to have minimal biological function\[^9,10\]. Depending on their function, exosome serves as a cargo vehicle for biologically active molecules to distant target tissue have been characterized\[^11,12\]. Based on the set of different biomolecules packed into the exosomes, the physiological effect it exerts on the target cells may differ. For example, the exosomes derived from embryonic stem cells are enriched with mRNAs and proteins that are responsible for maintaining pluripotency of the cells and can transfer it to the target cells like hematopoietic stem cells\[^13\]. Similarly, microRNAs (miRNAs) that are found in exosomes were shown to be transferred to the target cell and thus functionally silence the target gene\[^14,15\]. The exact mechanism
behind sorting of specific proteins or molecules inside exosomes are not known. Prior studies have shown that exosomes secreted from the same cells can be packed with different protein profiles thereby proving that exosomes are packed with selective proteins or miRNAs\(^{[16,17]}\). Thus, exosomes represent a novel mode of intercellular communication, which may play a major role in many cellular processes, such as immune response, antigen presentation and signal transduction\(^{[18,19]}\). Exosome secretion provides cells with an advantage to rapidly release selective molecules and change target cellular response to environmental stimuli or phenotype of the cell. The roles of exosomes on lung pathology are being increasingly described and are being appreciated as immunogenic potentiators especially in the context of allergy\(^{[20]}\). Studies to understand the role of EVs in determining the endotypes and phenotypes of asthma (i.e., mediating pro-inflammatory response) following different environmental insults may help in devising novel therapies for asthma.

**Plasma or serum EVs**

Plasma or serum samples are easy to obtain from patients with non-invasive procedures that cause minimal pain during sample collection. As miRNAs are known to be highly stable in body fluids, EVs containing miRNAs from serum samples are best suited to study EV biomarkers in asthma. In a recent study, an abundance of miR-122-5p and miR-191-5p were increased in plasma-derived exosomes from patients with asthma without any difference in asthma severity (moderate-severe)\(^{[21]}\). They showed levels of miR-122-5p positively correlated with blood eosinophil and neutrophil counts, but not lung function. Similarly, levels of miR-191-5p showed a negative correlation with lung function (FEV1% pred) and percentage of blood lymphocytes. Prior studies showed a strong correlation with blood eosinophils and neutrophils counts/percentages in patients with asthma based on the specific clinical phenotype/endotype of the disease\(^{[22,23]}\). Both miR-122-5p and miR-191-5p identified in plasma-derived exosomes from asthmatics (mild-to-moderate or severe eosinophilic asthma) compared to healthy controls may be used as novel biomarkers in asthma after validating these findings using a larger cohort of samples.

Previously, miR-122-5p was known for its proinflammatory property in myocardial infarction and liver diseases\(^{[24,25]}\). Prior report showed miR-122-5p expression was increased during lipopolysaccharide (LPS)-induced acute lung injury. Treatment with miR-122-5p inhibitor showed protection against inflammation and injury via modulating DUSP4 (dual specific phosphatase-4) and ERK1/2 signaling pathway\(^{[26]}\). Based on the prior report, miR-122-5p may play an important role during lung inflammation/injury and therefore by blocking miR-122-5p expression using a specific inhibitor may offer protection against chronic inflammatory lung disease such as asthma. On the contrary, miR-191-5p promotes inflammation by interacting with key proteins and mRNAs that control Th-2 differentiation and function of APCs\(^{[21]}\). Interestingly, miR-191 was also reported to target Bmal1, which is a core clock component that controls circadian rhythms in mouse liver cells\(^{[27]}\). Therefore, miR-191 may be a possible key mediator that connects the circadian rhythms-exosome-inflammation axis in asthma. Additional evidence from equine model of severe asthma showed differential expression of several miRNAs (eca-miR-128, eca-miR-744, eca-miR-197, eca-miR-103, eca-miR-107a, eca-miR-30d, eca-miR-140-3p, eca-miR-7, eca-miR-361-3p, eca-miR-148b-3p and eca-miR-215) in serum that regulates airway remodeling and CD4\(^+\) T cell maturation and differentiation\(^{[28]}\). In another human study, miR-125b and miR-126 were found to be increased in exosomes isolated from the serum of asthmatics\(^{[29,30]}\). Identifying plasma/serum-derived exosome containing miRNAs may shed light on the hidden molecular and cellular signaling mechanism that controls the immune status in asthma. Therefore, understanding the role of plasma/serum-derived EV miRNA signatures will be important for discovering new circulating biomarkers that can differentiate asthma phenotypes and may help develop targeted therapies in the future.

**Bronchoalveolar lavage fluid EVs**

The presence of exosomes in bronchoalveolar lavage (BAL) fluid was characterized for the presence of MHC II and co-stimulatory molecules like CD86 in normal human subjects\(^{[31]}\). Though exosomes carry
antigen-presenting and co-stimulatory molecules, they do not involve in antigen presentation. Rather they are taken up by professional APCs like dendritic cells, which helps in the activation of naïve T-cells. The impact of secreted exosomes in allergic airways has been assessed using animal models. Mice challenged with ovalbumin (OVA) or house dust mite (HDM) show increased secretion of exosomes with different miRNA profiles compared to control mice. Moreover, another similar study showed that treatment with inhibitors of exosome secretion (GW4869) decreased lung inflammation by reducing proliferation and chemotaxis of monocyte. Exosomes isolated from healthy control subjects and patients with mild intermittent asthma showed 24 differentially expressed miRNAs, which were related to airway inflammation. Let-7 and miRNA-200 family were able to discriminate asthmatics from normal subjects. In particular, miRNAs from miR-200 family that regulate epithelial-mesenchymal transition is downregulated in asthma. Pathway analysis revealed MAPK and JAK-STAT signaling pathway as the most significantly affected by a subset of exosomal miRNAs in asthma. A detailed total RNA profiling showed mRNA, miRNAs and other small RNAs (tRNAs, rRNAs, snoRNAs and piRNAs) were significantly altered among healthy controls and severe asthmatics. They showed that several of the miRNAs were downregulated in severe asthmatics (miR-625-3p, miR-202-5p, miR-202-3p, miR-568, and miR-151a-5p) associated with reduced lung function (FEV1) and asthma endotype/phenotype that involves neutrophilic (miR-224-5p, miR-581, miR-151a-5p, and miR-9-5p) and eosinophilic infiltration (miR-615-3p, miR-10b-5p and miR-151a-3p). Isolation and characterization of BAL fluid exosomes at the molecular level (miRNA profiling) from normal vs. asthmatics is an emerging area of research. Studying BAL fluid EVs, their function and their effect on bronchial epithelial cells may open a wide range of possibilities to understand the mechanism of disease and develop new therapeutic strategies.

Exosomes are known to carry many biologically active molecules, but recently it has been discovered that exosomes from BAL fluid contain mitochondria. Especially the exosomes isolated from BAL fluid of asthmatic patients contain more mitochondria compared to healthy volunteers. In addition, the study also showed that exosomes from the myeloid-derived regulatory cell (HLA-DR+) in BAL could deliver mitochondria to CD4+ T cells that induce oxidative stress in T cells to reduce inflammation. So far, many studies have delineated the pro-inflammatory property of exosomes, but a study conducted using BALB/c mice has demonstrated the tolerogenic (anti-inflammatory) effect of exosomes in vivo. When BAL fluid-derived exosomes from mice tolerated to olive pollen (Ole e1) were administered to BALB/c mice prior to allergen challenge inhibited IgE response, Th2 cytokine production and airway inflammation by increasing TGF-β in the lung. A significant portion of exosomes isolated from BAL fluid of patients sensitized to birch pollen contained mucin 1 indicating that they are mostly derived from bronchial epithelial cells. In addition, BAL fluid-derived epithelial exosomes were packed with leukotrienes synthesizing enzymes (LTA4H, LTC4S, FLAP, and 15-LO-1) and are highly capable of synthesizing LTB4 leukotrienes compared to antigen-presenting cells (APCs)-derived exosomes. It acts as both chemoattractant for subsets of T lymphocytes and activates lymphocytes as well as DCs. Elevated levels of LTB4 from BAL fluid have been reported to increase migration of DC to regional lymph nodes and cause airway hyperresponsiveness in vivo in mice.

Though most exosomes present in BAL fluid come from airway epithelial cells, a significant proportion of it also comes from resident alveolar macrophage (AM) that is present in the lung cavity. Suppressor of cytokine signaling 3 (SOCS3) plays a significant role in suppressing inflammatory cytokine response and its level were reduced in asthmatics and allergen challenged mice. A recent study showed AM-derived EVs were enriched with SOCS3 blocking both STAT3 and STAT6 in human bronchial epithelial cells (BEAS-2B), when challenged with IL-4/IL-13 and HDM. Interestingly, AMs treated with cytokines such as IL-4, IL-33, TSLP and IL-25 contained a very low amount of SOCS3 in both the EVs and cell lysates. SOCS3 loaded EVs from AMs may play an important role in the pathogenesis of asthma and synthetic SOCS3 encapsulated liposomes treated in cells and mouse model of allergic asthma showed attenuation of
Table 1. Extracellular vesicles secreted by structural and immune cells and their associated cellular and molecular functions

<table>
<thead>
<tr>
<th>EV secreted cell-types/sources</th>
<th>EV isolation and characterization methods</th>
<th>EV molecular signatures</th>
<th>Key findings/major outcomes</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAL fluid</td>
<td>Differential ultracentrifugation; Flow cytometry; Immunoelectron microscopy</td>
<td>HLA-DR (MHC II), CD54, CD63, CD86 and MHC I</td>
<td>Human BALF-exosomes are enriched with antigen-presenting molecules like MHC II (HLA-DR), MHC I, CD54 and co-stimulatory molecules like CD86</td>
<td>[31]</td>
</tr>
<tr>
<td>BAL fluid</td>
<td>Differential ultracentrifugation; Splice variant analysis</td>
<td>MHC I, MHC II and CD9; Presence of SP-B; Ole e 1 in BALF exosome from tolerized mice contains glycosylated and nonglycosylated forms of Ole e 1</td>
<td>BALF-exosomes from mice tolerized to Ole e 1 express blocks allergen-specific IgE and IgG, antibodies and reduced Th2 cytokines when pretreated with tolerogenic exosomes, but induces TGF-β</td>
<td>[38]</td>
</tr>
<tr>
<td>BAL fluid</td>
<td>Differential ultracentrifugation; FACS analysis</td>
<td>CD36, HLA-DR (MHC II), MUC1, LTA, H, LTA, s, FLAP and 15-LO-1</td>
<td>BALF-exosomes from asthmatics showed higher levels of CD81, CD63 and CD36 that correlate with HLA-DR</td>
<td>[39]</td>
</tr>
<tr>
<td>BAL fluid</td>
<td>Differential ultracentrifugation with modification; FACS analysis; Western blotting and FACS analysis</td>
<td>HLAII and CD63 (MHC class I, CD54 and CD86 were not detected); miRNAs: let-7c, let-7b, miR-141, miR-200b-let-7d, let-7a, miR-21, miR-27a, let-7e, miR-34c-5p, miR-19b, miR-0022, miR-0024, miR-0026a, miR-0099a, miR-0200c, miR-0202, miR-0203, and miR-0130a</td>
<td>MiRNAs detected in BALF exosomes from HDM-treated mice showed an 8.5-fold increase compared to sham control</td>
<td>[35]</td>
</tr>
<tr>
<td>BAL fluid</td>
<td>ExoQuick exosome precipitation method; qNano nanoparticle counter; TEM; Affymetrix Gene Chip miRNA 3.0 Array; qRT-PCR Validation</td>
<td>miRNAs: let-7a-5p, miR-702-5p, miR-762, miR-574-3p, miR-574-5p, miR-1827, miR-346, and miR-191-5p</td>
<td>BALF fluid EVs from HDM-treated mice showed an 8.5-fold increase compared to sham control</td>
<td>[34]</td>
</tr>
<tr>
<td>BAL fluid</td>
<td>Differential ultracentrifugation; NanoSight NS300; TEM; Image Stream analysis; Flow cytometry; SWATH lipidomic analysis</td>
<td>HLA-DR’ and CD54’ (ICAM-1); CD9’ CD63’ CD81’ TSG101’ Phosphatidylglycerol 34.2, ceramide-phosphate 28:0, and ceramide 34:2</td>
<td>Increased expression HLA-DR’ and CD54’ in BALF-derived EVs from asthmatics compared to healthy controls</td>
<td>[78]</td>
</tr>
<tr>
<td>BAL fluid</td>
<td>Differential ultracentrifugation; NanoSight NS300; TEM; Image Stream analysis; Flow cytometry; CryoEM</td>
<td>CD63, HLA-DR, mitochondrial DNA (mt-DNA) and mitochondria</td>
<td>EVs isolated from BAL fluid of asthmatics and myeloid-derived regulatory cells (MDRC)-derived exosomes contain mitochondria (MitoT-Green’ and mitochondrial DNA)</td>
<td>[37]</td>
</tr>
<tr>
<td>BAL fluid</td>
<td>Exo-Mir kit for nanovesicle RNA from 20 ml BAL fluid; Small RNA-seq analysis and Validation by qPCR</td>
<td>miRNAs: miR-625-3p, miR-202-5p, miR-202-3p, miR-568, miR-151a-5p, miR-615-3p, miR-10b-5p, miR-151a-3p, miR-224-5p, miR-581, and miR-9-5p</td>
<td>EVs isolated from BAL fluid of asthmatics and myeloid-derived regulatory cells (MDRC)-derived exosomes contain mitochondria (MitoT-Green’ and mitochondrial DNA)</td>
<td>[36]</td>
</tr>
<tr>
<td>NHBE and BAL fluid</td>
<td>Differential ultracentrifugation; TEM; Immunoblotting</td>
<td>Tissue factor (TF), EGFR, and Annexin V</td>
<td>Compression stress-induced TF-containing exosomes in differentiated normal human bronchial epithelial cells (NHBE)</td>
<td>[53]</td>
</tr>
<tr>
<td>BAL fluid/Epithelial cells</td>
<td>Differential ultracentrifugation; Bead-based assay; ELISA; TEM; Flow cytometry</td>
<td>MHC II, HSP70, CD63</td>
<td>IL-13 treatment induced exosome secretion in BEAS-2B cells to facilitate monocyte proliferation and chemotaxis</td>
<td>[33]</td>
</tr>
<tr>
<td>Epithelial cells</td>
<td>Differential ultracentrifugation with modifications; NanoLC-ESI MS/MS analysis; Immuno EM and flow cytometry</td>
<td>MUC1, MUC4, MUC16, SNA lectin (α-2,6-linked sialic acid), keratan sulfate (SD4), CD59, CD63, MHC class I and II</td>
<td>MUC4 is unique to human tracheobronchial epithelial cells (HTBE)-derived-exosomes and MUC3 and MUC18 are unique to Calu3-exosomes that confer innate immune defense to virus</td>
<td>[49]</td>
</tr>
<tr>
<td>Epithelial cells</td>
<td>Differential ultracentrifugation with modifications; NanoSight NS300; TEM; MS analysis; HTG EdgeSeq miRNA</td>
<td>Mucins (MUC3B, MUC13, MUC5AC and MUC5B) and miRNAs (miR-34/449, miR-223 and miR-29)</td>
<td>Mucin and sialic acid lectin enriched exosome confer innate immune defense against viral infection</td>
<td>[50]</td>
</tr>
<tr>
<td>NHBE</td>
<td>qEV columns (size-exclusion chromatography); ExoQuick-TC reagent; PMX 110 scanning ZetaView; TEM, SeramiR miRNA profiling; RT-qPCR</td>
<td>CD63, CD9 and CD81 miRNAs downregulated in IL-13 treated NHBEs: miR-210, miR-125a-5p, miR-34a, miR-92a, miR-21</td>
<td>IL-13 treatment alters the miRNA signatures (majority of the miRNAs were downregulated: e.g., miR-210, miR-125a-5p, miR-34a, miR-92b, miR-210, etc.) in apical and basal epithelial cell-derived EVs (both early vs. late) are involved in Th2 differentiation and DC maturation</td>
<td>[54]</td>
</tr>
<tr>
<td>Fibroblast</td>
<td>Differential ultracentrifugation with modification; TEM; flow cytometry</td>
<td>miRNAs: miR-335 miR-760, miR-632, miR-654-5p, miR-671-5p, miR-92a, miR-32, miR-101 and miR-21</td>
<td>Nasal lavage sEVs showed decreased expression of miR-34a, miR-92b and miR-210 correlated with airway obstruction in children</td>
<td>[7]</td>
</tr>
<tr>
<td>Dendritic cells</td>
<td>Differential ultracentrifugation with modification; Human microRNA microarray from Agilent; Flow cytometry</td>
<td>MDDCs exosomes and exosomes from T cells clone contain HLA-DR, CD63 and CD81</td>
<td>Exosomes from monocyte-derived dendritic cells (MDDC) carry Fel d 1 (cat allergen) and induce IL-4 production in PBMCs from cat-allergic individuals</td>
<td>[61]</td>
</tr>
<tr>
<td>Dendritic cells</td>
<td>Differential ultracentrifugation; NanoSight LM10; Immuno-EM; Flow cytometry</td>
<td>CD63 and C104L TSLP-activated DCs released exosomes that are enriched in C104L promote Th2 differentiation</td>
<td>Demonstrated distribution of aeroallergens via exosomes derived from DCs T lymphoblasts showed expression of CD2, CD18, CXCR4, and MHC I and to a lesser extent MHC II</td>
<td>[6]</td>
</tr>
<tr>
<td>Dendritic cells</td>
<td>Differential ultracentrifugation; ELISA; Flow cytometry</td>
<td>Microvesicles from Jurkat T cells and human CD4+ T cells and CD8+ T cells clone contain CD3ζ/ζ complex</td>
<td>Microvesicles from Jurkat T cells and T lymphoblasts expressed CD3ζ, TCR and CD63</td>
<td>[71]</td>
</tr>
<tr>
<td>T cells</td>
<td>Differential ultracentrifugation; flow cytometry</td>
<td>Microvesicles from Jurkat T cells (MDDC) and lymphoblasts showed expression of CD2, CD18, CXCR4, and MHC I and to a lesser extent MHC II</td>
<td>Microvesicles from CD3-activated Jurkat cells and lymphoblasts showed expression of CD2, CD18, CXCR4, and MHC I and to a lesser extent MHC II</td>
<td>[74]</td>
</tr>
<tr>
<td>T cells</td>
<td>Differential ultracentrifugation; Immunoelectron microscopy; FACS analysis</td>
<td>Microparticles from resting and activated T cells contain LFA1α/CD11α</td>
<td>Microvesicles from activated T cells induce cytokine release (IL-8 and oncostatin M) and activate ERK phosphorylation in human mast cells</td>
<td>[74]</td>
</tr>
<tr>
<td>T cells</td>
<td>Differential ultracentrifugation; Human microRNA microarray (Agilent); Flow cytometry</td>
<td>miRNAs are abundant in Jurkat-derived J77 T cell exosomes (miR-760, miR-632, miR-654-5p and miR-671-5p).</td>
<td>Differentially expressed miRNAs in T cells vs. T cell-derived exosomes: (upregulated: miR-760, miR-632, miR-654-5p and miR-671-5p) and (downregulated: miR-32, miR-101, miR-21)</td>
<td>[70]</td>
</tr>
<tr>
<td>T cells</td>
<td>Differential ultracentrifugation; flow cytometry; mass spectrometry analysis</td>
<td>Proteins: RAS, ZAP70, RASGRPI, AKT, CD63 and CD81</td>
<td>Jurkat T cell-derived exosomes transfer proteins of RAS/MAPK signaling pathways (RAS, ZAP70, RASGRPI and AKT) to mast cells and activate ERK phosphorylation in vitro</td>
<td>[73]</td>
</tr>
</tbody>
</table>
TCR activation leads to the secretion of exosomes from CD4⁺ CD25⁺ Treg cells. Other exosomes are released from DCs, B cells, mast cells, eosinophils, and neutrophils. Exosomes can induce immune suppression through adenosine production, and they can also induce T cell proliferation, increase cytokine secretion, and promote immune cell activation.

**Table 1**

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Extracellular Vesicles</th>
<th>Exosomal Proteins</th>
<th>Exosomal miRNAs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tregs</td>
<td>Differential ultracentrifugation, TEM; Flow cytometry</td>
<td>CD81, CD63, and CD73</td>
<td></td>
</tr>
<tr>
<td>B cells</td>
<td>Differential ultracentrifugation; Flow cytometry</td>
<td>MHC classes I and II, CD40, CD54, CD63, CD80, CD81, CD86 and CD19</td>
<td>miRNAs: miR-760, miR-632, miR-654-5p and miR-671-5p and miR-32</td>
</tr>
<tr>
<td>B cells</td>
<td>Differential ultracentrifugation; Flow cytometry</td>
<td>miRNAs: miR-760, miR-632, miR-5127-3p, and miR-671-5p</td>
<td></td>
</tr>
<tr>
<td>Eosinophils</td>
<td>Differential ultracentrifugation; NanoSight LM10; TEM, flow cytometry, Immunoblot analysis</td>
<td>Eosinophil peroxidase (EPO), Major basic protein (MBP), Eosinophil cationic protein (ECP)</td>
<td>miRNAs: miR-760, miR-632, miR-654-5p and miR-671-5p (upregulated) and miR-32 (downregulated)</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>Differential ultracentrifugation; NanoSight LM10; Immunoblot analysis</td>
<td>EPO, MBP, ECP and perioxidin</td>
<td>High number of eosinophil-derived exosomes with basic proteins (EPO, MBP, and ECP) were detected in eosinophils from patients with asthma compared to healthy controls</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>Differential ultracentrifugation</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>Differential ultracentrifugation and size-exclusion chromatography; electron microscopy; NICOMP 30 device; Nano-LC-MS/MS</td>
<td>Phosphatidylinositol-4-phosphate 5-kinase II (PI5KII), Phosphatidylcholine-sterol acyltransferase, Tenascin, Thrombospondin-1, Annexin A7, Neurogenic locus notch homolog protein 2, Lactotransferrin, Integrin-linked protein kinase, Protein S100A9, Fibrinogen Aα, α-1-acid glycoprotein 2, Lipocalin 2, Complement C3, Profilin-1, Triosephosphate isomerase, Integrin-β2, Hsp60 and hsc70</td>
<td>Identified proteins were differentially expressed between unstimulated vs. LPS-stimulated neutrophil-derived exosomes</td>
</tr>
<tr>
<td>Mast cells</td>
<td>Differential ultracentrifugation</td>
<td>Hsp60 and hsc70</td>
<td>MC-derived exosomes induce DC maturation in vitro</td>
</tr>
<tr>
<td>Mast cells</td>
<td>Differential ultracentrifugation; FACS analysis; Immuno-EM; ELISA and MALDI-TOF-MS</td>
<td>Hsp60, hsc70, MHC II, CD86, CD40, CD40L, LFA-1 and ICAM-1</td>
<td>BMMC-derived exosomes show selective enrichment of hsp60 and hsc70, and are capable of inducing DC differentiation into efficient APCs</td>
</tr>
<tr>
<td>Mast cells</td>
<td>Differential ultracentrifugation; FACS analysis; confocal microscopy</td>
<td>BMMC exosomes contained FcεRI</td>
<td>BMMC-derived exosomes showed reduced airway inflammation, AHR in the OVA-induced allergic asthma, and MC-derived EVs upregulate epithelial-mesenchymal transition markers (TGFβ, TWIST1, MMP9 and BMP7) at the transcript level in epithelial cells</td>
</tr>
</tbody>
</table>

**Footnotes:**

1. **AHR:** Airway hyperresponsiveness; **BMMC:** bone marrow-derived mast cell.

**References:**

[81] TCR activation leads to the secretion of exosomes from CD4⁺ CD25⁺ Tregs enriched in CD73 mediates immune suppression via adenosine production.

[76] B cell-derived exosomes can bind peptides derived from Bet v 1 (Birch peptides).

[70] B cell-derived exosomes loaded with Bet v 1 peptides can induce T cell proliferation as well as increase cytokine production in allergen-specific T cells.


[84] Eosinophil-derived exosomes were enriched with eosinophil granule proteins such as EPO, MBP and ECP without any significant difference among asthmatics vs. healthy controls.

[86] Eosinophil-derived exosomes produce ROS and NO.

[88] Eosinophil-derived exosomes from asthmatics increased expression of both angiogenesis and fibrosis markers (CCCR3 and VEGFA) in bronchial smooth muscle cells.


[92] BMMC-derived exosomes enriched in these surface markers (MHC II, CD86, CD40, CD40L, LFA-1 and ICAM-1) induces dendritic cells.

[94] BMMC-derived exosomes loaded with BSA when injected in mice stimulate B and T lymphocytes.

[97] BMMC-derived exosomes can bind to free IgE via FcεRI.
therapeutic opportunities to patients with asthma that remain uncontrolled despite intensive corticosteroid treatment.

**Nasal lavage fluid EVs**

Lasser *et al.*[^43] first reported the existence of EVs in nasal lavage fluid (NLF). They isolated NLF EVs using ultracentrifugation method and characterized by electron microscope, flow cytometer and Western blot analysis for EV-specific markers[^43]. Like BALF, EVs from the nasal cavity are important for studying inflammation as nose is the first line of defense against inhaled particles such as dust, allergens and air pollutant. Initial observation made by the same group showed that even nasal EVs from healthy subjects were able to promote migration of immune cells like neutrophil, monocyte, and NK cells. Mucin-7, Mucin-5B, Immunoglobulin J chain, polymeric immunoglobulin receptor, filaggrin and hornerin were differentially altered in asthma and asthma with chronic rhinosinusitis condition compared to control[^43]. Additionally, they also confirmed iNOS activity in isolated NLF EVs from healthy donors[^44]. Nasal mucous EVs from allergic rhinitis (AR) and healthy controls were characterized for the presence of CD63 and HLA-DR markers. Additionally, they showed 21 miRNAs upregulated and 14 miRNAs downregulated in nasal EVs from AR group compared to healthy controls. Among them, 4 miRNAs (miR-30-5p, miR-199b-3p, miR-28-3p and miR-874) that are involved in B cell receptor signaling pathway were differentially expressed in nasal EVs from AR[^45]. In a recent study, NLF EVs from asthmatics contained higher amounts of tenascin-C (TN-C) an immunomodulatory extracellular matrix protein in response to human rhinovirus

---

[^43]: Lasser *et al.*[^43] first reported the existence of EVs in nasal lavage fluid (NLF). They isolated NLF EVs using ultracentrifugation method and characterized by electron microscope, flow cytometer and Western blot analysis for EV-specific markers[^43]. Like BALF, EVs from the nasal cavity are important for studying inflammation as nose is the first line of defense against inhaled particles such as dust, allergens and air pollutant. Initial observation made by the same group showed that even nasal EVs from healthy subjects were able to promote migration of immune cells like neutrophil, monocyte, and NK cells. Mucin-7, Mucin-5B, Immunoglobulin J chain, polymeric immunoglobulin receptor, filaggrin and hornerin were differentially altered in asthma and asthma with chronic rhinosinusitis condition compared to control[^43]. Additionally, they also confirmed iNOS activity in isolated NLF EVs from healthy donors[^44]. Nasal mucous EVs from allergic rhinitis (AR) and healthy controls were characterized for the presence of CD63 and HLA-DR markers. Additionally, they showed 21 miRNAs upregulated and 14 miRNAs downregulated in nasal EVs from AR group compared to healthy controls. Among them, 4 miRNAs (miR-30-5p, miR-199b-3p, miR-28-3p and miR-874) that are involved in B cell receptor signaling pathway were differentially expressed in nasal EVs from AR[^45]. In a recent study, NLF EVs from asthmatics contained higher amounts of tenascin-C (TN-C) an immunomodulatory extracellular matrix protein in response to human rhinovirus.
infection. They showed that TLR3, but not TLR7, activation in primary human lung epithelial cells and BEAS-2B cells resulted in TN-C associated EV release. These studies demonstrate TN-C associated EVs are relevant to the biology of viral-induced airway inflammation and exacerbations in asthmatics\[46\]. Compared to BAL fluid, NLFs are easier to collect and process for EV isolation. NLF has a greater advantage over BAL fluid as the nasal cavity forms the first line of defense against allergen and environmental insults. Therefore, early changes in EV release can be detected in nasal exosomes.

**Sputum EVs**

Limited studies are available that utilized sputum EVs in asthma. In a study, miRNA signatures from sputum EVs were analyzed in asthmatics. Sputum EVs contained exosome surface markers like CD9, CD63, and HLA-DR as measured by flow cytometry in induced sputum obtained from mild allergic asthma patients before and after allergen challenge. However, there was no significant difference in the surface markers and types of RNA present in sputum exosomes\[47\]. In another study, increased expression of sputum miRNAs (miR-223-3p, miR-142-3p and miR-629-3p) was associated with neutrophilic airway inflammation in mild to moderate and severe asthmatics. All the three miRNAs were upregulated in patients with severe asthma compared to mild asthma\[48\], showing a positive correlation with sputum neutrophil percentage and a negative correlation with sputum macrophage percentage\[49\]. The later study reported miRNA transcript levels in sputum sample rather than sputum EVs. Since miRNAs are richly packed in EVs from most biological fluids, this may be correlated with sputum EVs. Future studies exploring miRNA signatures from sputum EVs may be used as a potential diagnostic biomarker to differentiate asthma endotype or phenotypes (e.g., neutrophilic vs. eosinophilic asthma).

**Epithelial cell-derived EVs**

Epithelial cells are considered an inert physical barriers that protect against inhaled pathogens or allergens. Apart from providing physical and chemical barriers through mucus production, epithelial cells also modulate the immune response to pathogens and allergens evading the mucosal barrier. *In vitro* experiments revealed that exosome exchange between human tracheobronchial epithelial cells (HTBE) and Calu3 cells elevated mucin production (MUC5B and MUC5AC) in HTBE cells, and they are responsible for viscoelastic properties of airway mucus and airway remodeling *in vivo*. Also miRNAs miR-34/449, miR-223 and miR-29 involved in cilia biogenesis were found to be abundant in HTBE exosomes after exosomal exchange\[49\]. Epithelial cells are sensitive to external environmental stimuli such as allergens, bacterial and viral infections, or air pollutants and modulate the innate and adaptive immune response against them. HTBE secretions containing exosome-like vesicles rich in MUC1, MUC4, MUC16, and SNA lectin (α-2,6-linked sialic acid) have been shown to provide innate immune defense against lung pathogens\[49,50\]. Damage to epithelial cells caused by environmental exposure is a common feature in asthma. Ezrin a cytoskeletal protein found on exosomes has been reported to be downregulated in the serum of severe asthmatic patients, with airway epithelial damage caused by IL-13 overexpression\[51,52\]. Tissue factor is another protein present in epithelial cell-derived exosomes involved in airway inflammation and remodeling\[53\] [Table 1 and Figure 1]. Therefore, proteomic analysis of epithelial cell-derived EVs or BAL fluid exosomes could lead to the identification of a potential new circulating biomarker and novel therapeutic targets for the treatment and management of asthma.

Most of the immunomodulatory effects of epithelial cells were assigned to their cytokine profile, but later studies have shown that exosomes secreted from epithelial cells induced proliferation and chemotaxis of monocytes. On the other hand, inhibition of exosome secretion using an inhibitor (GW4869) is reported to reduce the proliferation of monocytes\[54\]. Depending on the miRNA profile of exosomes secreted by epithelial cells can affect the Th2 polarization and DC maturation response to an allergen or cytokine stimulation. IL-13 treatment in normal human bronchial epithelial cells modulated miRNA profile in secreted exosomes. The study showed miR-34a, miR-92b and miR-210 were significantly decreased in
exosomes secreted from epithelial cells. All three miRNAs were involved in the regulation of immune cells, e.g., miR-34a is mainly involved in the differentiation of DCs and DC-mediated T cell activation. Similarly, miR-210 and miR-92b are involved in Th1 and Th17 differentiation and epithelial-to-mesenchymal transition, respectively. Furthermore, future studies on molecular characterization of small RNAs using next-generation sequencing approaches will be possible to predict the difference in endotypes or phenotypes of asthma. Thus, it will enhance our understanding to develop alternative approaches that may be used for treating severe asthmatics. The stability of exosomes isolated from different sources and temperature conditions makes it difficult for further analysis of functional exosomes.

**Dendritic cell-derived EVs**

DCs play a key role in detecting and directing immune response at the mucosal surface where they constantly sample antigens. This allows them to determine T cell activation and polarization towards Th1, Th2, Treg, or Th17. Dendritic cells are well known for their antigen-presenting properties, but they can also secrete exosomes bearing allergens on MHC II. A prior study showed that Fel d1 containing exosomes secreted by monocyte-derived dendritic cells (MDDCs) was able to elicit IL-4 cytokine response in PBMCs isolated from patients, allergic to cat allergen and not in healthy volunteers. In addition, those exosomes can also acquire free allergens and cause the production of IL-4 cytokine in PBMCs of allergic patients. They also found that Fel d1 alone caused a similar response in PBMCs, so it is highly doubtful whether the observed effect is due to exosomes or allergen itself. Apart from allergens, exosomes also carry various protein ligand-like OX40L that can specifically help in the proliferation and differentiation of naïve CD4+ T cells to Th2 cells. Not only the exosomes secreted by dendritic cells, but those secreted by other cells can be taken up by dendritic cells also determine the immunoregulatory effect of DCs. Dendritic cells can also inhibit the differentiation of Th1 and promote Th2 through the STAT3 pathway by secreting exosomes packed with miR-21. These studies implicate that allergic airway inflammation and immune response during asthma can be reduced or exaggerated depending on the miRNA cargo present in DC-derived exosomes.

Most of the studies on dendritic cell-derived exosomes were primarily conducted either using BMDCs or MDDCs. The specific dendritic cell subsets like conventional types 1 and 2 dendritic cells (cDC1, cDC2s) and plasmacytoid dendritic cells have a very different role in asthma pathogenesis compared to other types. cDC1s are known for promoting CD8+ T cell response, but upon HDM or OVA exposure they induce T cells to differentiate into T reg by producing retinoic acid and activating peroxisome proliferator-activated receptor γ. This helps cDC1s to suppress Th17 and Th2 differentiation upon allergen challenge. On the other hand, cDC2s are efficient in taking up allergen and effectively migrate towards myeloid lymph nodes to induce Th2 differentiation after allergen challenge in lung airways in animal models. This emphasizes the need for extensive research that will thoroughly isolate and characterize EVs from specific subsets of dendritic cells to understand the mechanism by which allergens dictate the immune response differentially among individuals in a population. This will help in the clinical diagnosis of the endotypes or phenotypes of asthma and direct patients with better alternative therapies, especially among severe asthmatics.

**T and B cell-derived EVs**

T cells play a major role in the adaptive immune response during asthma pathogenesis, which are involved in IgE antibody class switching, Th2-related cytokine production, eosinophil recruitment and survival. The mouse model of allergic asthma has established that Th2-mediated immune response is necessary to reproduce features of human asthma. APC-dependent allergen priming of CD4+ T cells decides the endotype and phenotype of asthma. During this process, T cells form an immune synapse with APCs and secrete exosomes in an antigen-driven unidirectional transfer of exosomal miRNAs toward APCs.
mechanism ensures cellular communication between antigen-presenting cells and T cells for effective activation. Prior research demonstrates that T cell activation induces exosomes enriched in surface markers such as TCR-β, CD3ε, CD2, LFA-1 and CXCR4. The exact role of T cell activation-mediated exosome release remains largely unknown, but it has been speculated that they may interact with APCs complement peptide on MHC II to facilitate their function in target cells. In another in vitro study, T cells activated by IL-2 and CD3/CD28 produced EVs enriched in specific tRNAs that repress the activation of CD4+ T cells. It was hypothesized that by utilizing EV biogenesis pathway, T cells get rid of tRNAs that repress its activation as antisense oligonucleotides against the specific tRNA enhance the activation of CD4+ T cells.

T cells are also responsible for mast cell activation, which has severe consequences in airway inflammation during asthma. Exosomes secreted from activated T cells have been reported to deliver activated Ras GTPase, ZAP70, RASGRP1 and AKT protein to mast cells thereby enhancing mast cell activation in airways. Th2-mediated inflammation is also promoted by B cell exosomes that are carrying allergen peptides on MHC molecules. There has always been a concern about whether B cells can prime naive CD4+ T cells as they are not professional APCs. In a recent study, B cells have been shown to promote Th2 cytokine response through antigen presentation. Additionally, they showed B cell-restricted MHC II expressing mouse develops Th1 and Th17 immune response when challenged with HDM, but fails to develop Th2 response. The antigen-presenting property of B cell-derived exosomes was shown using in vitro experiments. The study showed that birch allergen (Bet v1) loaded B cell exosomes induce T cell proliferation and secretion of IL-5 and IL-13 cytokines, which are key drives of airway inflammation and remodeling in asthma [Table 1 and Figure 1]. The immunostimulatory effect of B cell exosomes may play an important role in driving Th2 response in vivo. This indicates that the complex interaction and communication between immune cells and APCs dictate specific phenotypic changes during the pathogenesis of asthma.

In a therapeutic approach, Treg cells hold a special place in asthma research as they can effectively ameliorate airway inflammation. Unique lipid signatures from airway exosomes are also reported to promote Th2 and Th17 polarization by modulating membrane fluidity. Exosomes secreted by Tregs are referred to as tolerosomes that are quantitatively higher compared to other types of T cells and are regulated by intracellular calcium level and synthesis of sphingolipid. CircRNA has been isolated and characterized from Treg exosomes, which have been proposed to function as RNA or protein decoy that modulates gene expression. The exact mechanism and function of CircRNA remain unclear. This is another area where more research is needed to better understand the role of Treg-derived EVs in the pathogenesis of asthma.

Repeated exposure of low-dose allergen results in the development of regulatory T cells in the lung, so Tregs may be used as a potential therapeutic target for severe asthma. Targeting Treg response in asthma may be an indispensable therapeutic approach, as bacterial exosome (Pseudomonas aeruginosa) sensitization in OVA challenged mice show reduced serum levels of IgE, Th2 response and increased Tregs in the lungs. Hence, exosomes secreted by Tregs have been implicated to suppress the inflammatory response in different acute and chronic inflammatory diseases. Lack of cell-specific markers to identify the origin of cell-type specific exosome makes it difficult to characterize them in mixed population of EVs from different biofluids. As different types of T cell-specific exosomes carry different sets of miRNAs, they have a wide range of biological functions in asthma. Determining the specific mechanism by which T cell-derived exosomes control other immune cells may be used as a novel biomarker or therapeutic target to treat asthma.
Eosinophil-derived EVs

One of the prominent features of asthma is eosinophilia and eosinophils are linked with T2 asthma endotype. Eosinophils from asthma patients release more exosomes and they are enriched with eosinophilic proteins like eosinophil peroxidase, major basic protein and eosinophil cationic protein\(^{[44]}\). Eosinophil-derived exosomes in healthy and asthmatic conditions share common proteins and are not much different from one another. The only real difference observed was the number of exosomes secreted in asthma patients compared to healthy controls\(^{[86]}\). It also induces apoptosis in epithelial cells impeding wound closure and smooth muscle proliferation\(^{[86]}\). Eosinophil-derived EVs are unlike any other EVs, there is no report regarding eosinophil-derived EVs or exosomes containing miRNAs or other biomolecules. Limited studies are available that demonstrate the role of eosinophil-derived EVs in asthma\(^{[84,86]}\) [Table 1 and Figure 1]. Further studies to characterize the exosomal cargo present in eosinophil-derived EVs such as miRNAs and lipid profiles may lead to a better understanding of how eosinophil-derived EVs alter airway remodeling and hyperresponsiveness during asthma.

Neutrophil-derived EVs

A small but significant number of people represent asthma with neutrophilia in airways and they have a poor clinical outcome with steroid treatment, unlike eosinophilic asthma. Although neutrophil infiltration can be seen in most asthma endotypes or phenotypes, it is more common in severe asthma\(^{[87]}\). Neutrophils play an important role in airway remodeling, inducing allergic inflammation by secreting cytokines, MMP9 and exosomes loaded with LTB4 or its synthesizing enzymes. Neutrophil-derived exosome induces smooth muscle cell proliferation as a result of their uptake by airway smooth muscle (ASM) cells\(^{[88,89]}\) [Table 1 and Figure 1]. The proliferation of ASM cells can lead to airway remodeling and airway hyperresponsiveness leading to exacerbation of asthma in severe asthmatics. Additional studies to isolate and characterize neutrophil-derived EVs are needed to better understand their role in the pathogenesis of severe asthma where neutrophilic infiltration plays a crucial role.

Mast cell-derived EVs

Mast cells (MC) are known for their IgE-mediated effector function in host defense against parasites and allergens. Prior reports have demonstrated the role of mast cells in both innate as well as an adaptive immune response\(^{[68]}\). Exosomes from mast cells loaded with antigen (BSA, transferrin and OVA), hsp60 and hsc70 promote DC maturation and antigen presentation of DCs to T cells, thus providing additional evidence that antigen-loaded exosomes facilitate priming of naïve T cell\(^{[90]}\). Mast cells treated with IL-4 were able to produce active exosomes that contain immunologically relevant molecules like MHC-II, CD86, LFA-1 and ICAM-1. Therefore, mast cells can activate T and B lymphocytes through exosomes. Antigen-loaded exosomes from mast cells can mount antigen-specific immune response along with DCs\(^{[62]}\). Protein and RNA expression analysis revealed many targets that are involved in asthma pathogenesis. Exosome from bone marrow-derived mast cell (BMMC) carrying FcɛRI inhibits IgE-mediated MC activation, whereas exosomes secreted by FcɛRI activation in MC can cause pro-inflammatory response\(^{[93-95]}\). MC exosomes also help in shuffling miRNA between CD34\(^+\) progenitor cells, controlling maturation processes\(^{[96]}\). Airway remodeling is one of the known features in asthma, and epithelial to mesenchymal transition (EMT) plays a significant role in remodeling. MC exosomes were able to initiate a phosphorylation cascade of proteins involved in EMT and upregulate matrix metalloproteases and TGF-β\(^1\)\(^{[97]}\) [Table 1 and Figure 1]. Therefore, identifying novel ways to selectively inhibit specific protein cargo packaged into mast cell-derived EVs might protect against airway inflammation and remodeling in asthma.

Mesenchymal stem cell-derived EVs

Mesenchymal stem cells (MSCs) are non-hematopoietic stem cells capable of differentiating into osteocytes, adipocytes, chondrocytes and hepatocytes. They are found in adipose tissue, bone marrow and umbilical cord. MSCs have been reported to have an immunomodulatory effect in the microenvironment of tissue by
secreting cytokines, immune receptors and EVs/exosomes. A recent study demonstrates that exosomes secreted by mouse adipose tissue-derived mesenchymal stromal cells (AD-MSC) decreased interleukin-6 (IL-6), IL-10 and transforming growth factor-β (TGF-β) cytokine release by DCs. It also reduced DCs capacity to induce lymphocyte proliferation and suppressed maturation of bone marrow-derived dendritic cells (BMDCs). Previous studies showed administration of conditioned media or exosomes secreted from bone marrow-derived MSCs or other sources attenuating chronic pulmonary disease. Bone marrow-derived MSC exosomes rather than MSC themselves were effective in reducing IL-10 and TGF-β release by PBMCs from asthmatics. Moreover, incubation of MSC exosomes with PBMCs increased Treg population and MSC administration in some cases have been reported to cause vascular occlusion and mal differentiation of MSCs. Using exosomes that have the same or better anti-inflammatory effect could help reduce the undesirable outcomes of the disease [Table 2 and Figure 2].

**Table 2. Mesenchymal stem cell (MSC)-derived EVs as novel therapeutics for allergic asthma**

<table>
<thead>
<tr>
<th>EV secreted cell-types</th>
<th>EV isolation and characterization methods</th>
<th>EV molecular signatures</th>
<th>Key findings/major outcomes</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSCs</td>
<td>Differential Ultracentrifugation; NanoSight NS300; TEM</td>
<td>-</td>
<td>Administration of either mMSC or hMSC-derived EVs differentially reduced airway hyperresponsiveness, lung inflammation, and Th1, Th2 and Th17 cytokines in Aspergillus hyphal extract-induced allergen model</td>
<td>[102]</td>
</tr>
<tr>
<td>Human AD-MSCs</td>
<td>Differential Ultracentrifugation; Zetasizer Nano ZS90 system; SEM</td>
<td>-</td>
<td>Human adipose tissue-derived MSC (AD-MSC)-derived EVs reduced eosinophil counts in the lung tissue and BALF associated with reduced airway inflammation and remodeling in OVA-induced allergic asthma</td>
<td>[104]</td>
</tr>
<tr>
<td>Mouse AD-MSCs</td>
<td>Bead-based isolation method; Dynamic light scattering (DLS); SEM; TEM</td>
<td>CD86, CD40, CD11c</td>
<td>Murine AD- MSC-derived exosomes reduced LPS-induced IL-10, IL-10, and TGF-β cytokine release in DCs</td>
<td>[99]</td>
</tr>
<tr>
<td>Human BM-MSC</td>
<td>Differential Ultracentrifugation; TEM</td>
<td>CD9, CD81</td>
<td>Lymphocyte proliferation was reduced in DCs treated with MSC-derived exosomes MSC-derived exosomes suppressed the maturation of BMDCs that are key players in modulating DC-induced immune response</td>
<td>[101]</td>
</tr>
<tr>
<td>Human iPSC MSC</td>
<td>Differential ultracentrifugation; Anion-exchange chromatography; TEM</td>
<td>CD9, CD63, CD81</td>
<td>Human MSC-derived small EV (seV) blocked IL22 function in PBMCs from patients with allergic rhinitis in response to IL-2/IL-25/IL-33</td>
<td>[103]</td>
</tr>
<tr>
<td>Human BM-MSC</td>
<td>Differential Ultracentrifugation; TEM; NTA</td>
<td>miR-21-5p, miR-142-3p, miR-126-3p</td>
<td>Labeled MSC-EVs preferentially targets DCs when co-cultured with T cells as shown by colocalization of MSC-EVs and DCs MSC-EVs treated immature DCs reduced uptake of FITC dextran suggesting their role in inhibiting DC maturation and antigen presentation MSC-EVs impairs DC migration to lymph nodes by reducing CCR7 expression MSC-EVs contained miRNAs (miR-21-5p, miR-142-3p, and miR-126-3p) which exerts an effect on DC maturation and function</td>
<td>[107]</td>
</tr>
</tbody>
</table>
Studies have also shown that exosomes from human MSCs were effective in reducing Th2 and Th17 cytokines and migration of neutrophil, macrophage and lymphocytes into the lung and BAL fluid in a mouse model of *Aspergillus* hyphal extract-induced allergic airway disease. Innate lymphoid cell type 2 (ILC2) plays a very crucial role in airway inflammation and asthma. ILC2 mainly secretes IL-5, a cytokine that acts as a chemoattractant for eosinophils. MSC EVs were able to reduce IL-9 and IL-13 in ILC-2, when incubated with PBMCs from patients with allergic rhinitis. In the same study, MSC EVs were able to reduce ILC2 population in the lung, BALF cytokines (IL-5 and IL-13), eosinophil and neutrophil counts in mouse intratracheally administered with recombinant IL-33. In an ovalbumin model, exosomes derived from adipose tissue MSCs were able to reduce eosinophils, IL-4, IL-5, Eotaxin and CD4+ T cells in the lung and thymus. Additionally, they also showed exosomes from MSCs were able to prevent airway remodeling and improve lung mechanics. Anti-inflammatory effects of MSC EVs have been reported in a human study, where the patients affected by graft vs. host disease were treated with MSC EVs enriched with anti-inflammatory cytokines like IL-10 and TGF-β1. MSC EVs treatment in patients reduced their steroid dosage significantly. This could be tested in patients with asthma as IL-10 and TGF-β1 were reported to play an important role in reducing airway inflammation [Table 2 and Figure 2].

Another report, human bone marrow MSCs-derived EVs reduced maturation markers like CD83, CD38 and CD80 in dendritic cells. It also reduced the production of pro-inflammatory cytokines such as IL-6 and IL-12p70 and increased anti-inflammatory cytokine TGF-β1. The same study showed that miR-21-5p targeted CCR7 receptor degradation in DCs leading to decrease in response to CCL21 and reduced migration into T cell-rich area in the secondary lymphoid organ. This could lead to reduced T cell response to allergen thereby reducing inflammation and possibly eosinophilia or neutrophilia. Another candidate
miRNA enriched in MSC EVs is miR-126-3p, which abrogates Th2 response by targeting POU domain class 2 associating factor 1, which indirectly downregulates GATA3 via PU.1 in HDM-induced allergic asthma in BALB/C mice [107-109]. On the other hand, miR-142-3p and miR-223-3p were enriched in MSC EVs that augment inflammation by increasing alveolar smooth muscle cell proliferation associated with eosinophilic and neutrophilic infiltration [106,110]. Human bone marrow-derived MSC EVs containing miR-1470 show anti-inflammatory properties by increasing FOXP3+ Tregs in PBMCs from acute asthmatics. miR-1470 in MSC EVs targets c-Jun mRNA in T cells thereby upregulating P27KIP1 which promotes Treg differentiation [112]. Therefore, MSC EVs rather than MSCs themselves may be used as novel therapeutics for the treatment of asthma [Table 2 and Figure 2].

Circadian rhythms and EVs
Evidence from the literature suggests that EVs could be key regulators of circadian rhythms synchronization between the “donor clock” and “recipient clock” [113]. The online EV database such as EVpedia and vesiclepedia provides us with sufficient data that relate to the presence of several proteins/mRNA and miRNAs in EVs [114-116]. The proteins such as PER2, PER3, CK1 families, AMPK, AMPK, GSK-3α, and GSK-3β and other miRNAs such as miR-27b-3p, miR-132, miR-142, miR-192, miR-194, miR-219a, miR-219b, miR-433 and miR-494 were present in EVs. The presence of these miRNAs in EV cargos could regulate clock function in recipient cells. It is noteworthy to determine how EVs participate in cell-to-cell communication between donor vs. recipient cells via clock-related molecules and mediate their function locally in tissues and systemically in the circulation [113]. Here are a few examples: EVs are responsible for modulating posttranslational modification of clock targets such as GSK3 (phosphorylation), thereby regulating core clock molecules BMAL-CLOCK and CRYs [117]. Additional reports suggest that non-coding RNAs in EVs essentially participate in the AMPK-mediated regulation of CRYs [118]. Specific miRNAs such as miR-132 and miR-219 have been shown to regulate PERs in a cell-type/tissue-specific manner [119-121]. A prior report showed a few of the circulating miRNAs such as miR-142-3p, miR-152 and miR-494 demonstrate diurnal oscillation (peaks at mid-day) and participate in the post-transcriptional regulation of Bmal1 [122]. In another study, an immune cell type specifically macrophage-derived exosomes containing miR-155 mediates suppressed proliferation and enhanced inflammation in fibroblasts during cardiac injury [123]. However, it is unclear if these miRNAs are present in EVs as well or only present as freely circulating miRNAs in serum and how specific miRNAs target the clock-controlled genes (e.g., bmal1, clock, mtd1, nrd12, per1-2, cry1-2, etc.) need to be further explored. A study from mouse model that mimics chronic night shift work revealed changes in plasma EVs, expression of clock genes in target tissues associated with altered metabolic function, and increased permeability of the colonic epithelial cell barrier [124].

The first evidence to demonstrate circadian variation exists in the release of EVs locally in lung tissue/bone marrow cells or systemically in the circulation comes from C57BL/6J mice entrained to a regular light-dark cycle (LD:12/12) [125]. EV isolation was performed in lung tissue, whole bone marrow cells and peripheral blood samples collected at 5 different circadian time points (ZT4, ZT8, ZT12, ZT16 and ZT24) revealed time of day-dependent difference in EV concentration [125]. Co-culture experiments showed lung-derived EVs alter transcript level of pulmonary specific mRNA and showed a time-dependent change in the uptake of EVs that modulate transcription (increased uptake at ZT20-ZT24) [125]. Another report shows the diurnal variation in circulating microvesicles (MVs) (CD41+ and Annexin V+) to the severity of obstructive sleep apnea (OSA) and the effect of continuous positive airway pressure treatment implicating the role of MVs in the pathobiology of OSA [126]. A recent report shows that plasma-derived exosomes from patients with OSA promote endothelial cell senescence (increased p16 and reduced SIRT1 and SIRT6 levels) via oxidative stress-related pathways [127]. Additionally, another report using a rat model showed circadian variation in the release of small EV/exosome marker protein. Tumor susceptibility gene 101 (TSG101) displays a circadian pattern to release urinary small EVs (concentration) and that can be used to normalize circadian variation...
while testing for new EV biomarkers\textsuperscript{[124]}\textsuperscript{[124]}. Overall, these data together suggest that circadian rhythms could play a vital role in modulating EV-mediated cell-to-cell communication locally in the lung and systemically in the circulation during normal (healthy) \textit{vs.} diseased state (asthma) that requires thorough investigation in the future. To date there exist no reports that directly link circadian rhythms, EVs, and asthma pathobiology. Furthermore, based on the evidence from the literature there is a strong connection between circadian rhythms and asthma. However, future research will hold accountable to find the missing link and direct role of EVs in circadian rhythms and asthma pathophysiology using novel \textit{in vitro} and \textit{in vivo} approaches.

CONCLUSIONS AND FUTURE DIRECTIONS
EVs have demonstrated their prime role in causing augmented immune-inflammatory response and airway remodeling during asthma. Additionally, EVs/exosomes from specific cell types such as mesenchymal stem cells and T cells have been shown to mediate protection against chronic inflammatory lung disease. Novel drugs or small molecules that can specifically target EV/exosome trafficking\textsuperscript{[126]}\textsuperscript{[126]} like calpeptin, manumycin A and Y27632, and lipid metabolism such as pantethine, imipramine and GW4869 may help reduce EV-mediated activation of target cells in asthma but will require further investigation. Future studies should investigate how EVs themselves or engineered with specific agents/drugs as biological vehicles can be used to reduce airway inflammation and remodeling in asthma. EVs as novel circulating biomarkers that can be used in the diagnosis, prognosis and therapeutics are expanding further due to the available tools and emerging isolation and characterization technologies\textsuperscript{[136]}\textsuperscript{[136]} such as genomics/transcriptomics, lipidomics, proteomics, metabolomics and high-throughput screening to better understand the role and function of EVs in heath and disease of several different chronic inflammatory lung conditions. Overall, there is a greater need to address the knowledge gap to understand the role of EVs relating to chronic lung diseases. Future studies will provide deeper insights into the complex link between different cellular processes such as circadian rhythms, and associated molecular mechanisms that relate to EV biogenesis, trafficking, cargos (e.g., miRNAs, proteins, lipids, \textit{etc.}), their function and EV-mediated signal transduction that occurs during the pathophysiology of allergic asthma.

DECLARATIONS
Acknowledgments
The authors would like to thank Mr. Allan Giri for his help in thoroughly editing the manuscript.

Authors’ contributions
Conceived and designed the outline of this article: Sundar IK
Prepared the initial draft and compiled all the sections: Srinivasan A, Sundar IK
Prepared the tables and figures: Srinivasan A, Sundar IK
Edited and revised the manuscript: Srinivasan A, Sundar IK
All authors approved the final version of the manuscript.

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was supported in part by a grant from the National, Heart, Lung, and Blood Institute (NHLBI) of the U.S. National Institute of Health (NIH) R01 HL142543 (Sundar IK) as well as the University of Kansas Medical Center, School of Medicine, Internal Medicine Start-Up Funds (Sundar IK).

Conflict of interest
The authors declare that this research work was conducted in the absence of any commercial or financial
relationships that could be construed as potential conflicts of interest. The updated review of literature and conclusions in this review article are solely those of the authors and do not represent the official views of the National Institute of Health (NIH)/National, Heart, Lung, and Blood Institute.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES


55. Hashimi ST, Fulcher JA, Chang MH, Gov L, Wang S, Lee B. MicroRNA profiling identifies miR-34a and miR-21 and their target genes...


Fu CL, Ye YL, Lee YL, Chiang BL. Effects of overexpression of IL-10, IL-12, TGF-beta and IL-4 on allergen induced change in bronchial responsiveness. Respir Res 2006;7:72.


Zhuansun Y, Du Y, Huang F, et al. MSCs exosomal miR-1470 promotes the differentiation of CD4+CD25+FOXP3+ Tregs in asthmatic patients by inducing the expression of P27KIP1. Int Immunopharmacol 2019;77:105981.


Arslan F, Lai RC, Smeets MB, et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate
<table>
<thead>
<tr>
<th>Reference</th>
<th>Title</th>
<th>Journal</th>
<th>Year</th>
</tr>
</thead>
</table>